Algorae Pharmaceuticals Limited
LVCLF
$0.0063
$0.000916.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 14.00K | 28.40K |
| Total Other Revenue | 82.50K | 82.50K | 82.50K | 55.20K | 28.40K |
| Total Revenue | 82.50K | 82.50K | 82.50K | 55.20K | 28.40K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 82.50K | 82.50K | 82.50K | 55.20K | 28.40K |
| SG&A Expenses | 223.50K | 462.40K | 701.50K | 698.90K | 698.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 641.20K | 914.50K | 1.19M | 1.20M | 1.22M |
| Operating Income | -558.80K | -832.10K | -1.10M | -1.14M | -1.19M |
| Income Before Tax | -855.60K | -1.12M | -1.37M | -1.43M | -1.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.86 | -1.12 | -1.37 | -1.43 | -1.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -855.60K | -1.12M | -1.37M | -1.43M | -1.49M |
| EBIT | -558.80K | -832.10K | -1.10M | -1.14M | -1.19M |
| EBITDA | -283.30K | -692.20K | -1.10M | -1.14M | -1.19M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 6.75B | 6.70B | 6.65B | 6.37B | 6.10B |
| Average Diluted Shares Outstanding | 6.75B | 6.70B | 6.65B | 6.37B | 6.10B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |